Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efzofitimod · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| efzofitimod 450 mg | EXPERIMENTAL | Administered IV infusion |
| efzofitimod 270 mg | EXPERIMENTAL | Administered IV infusion |
| Placebo | PLACEBO_COMPARATOR | Administered IV infusion |
| Name | Type | Description |
|---|---|---|
| efzofitimod 450 mg | DRUG | IV infusion over approximately 60 minutes every 4 weeks |
| efzofitimod 270 mg | DRUG | IV infusion over approximately 60 minutes every 4 weeks |
| Placebo | DRUG | IV infusion over approximately 60 minutes every 4 weeks |
Inclusion Criteria: 1. Diagnosis of SSc based on ACR/ EULAR criteria (2013) 2. Overall duration of SSc \< 84 months from the first non-Raynaud symptom manifestation prior to Day 1 3. HRCT obtained at the Screening Visit or within the 3 months prior to Screening consistent with SSc-ILD (adjudicated ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 2 | PHASE3 | Belimumab |
| United Therapeutics Corporation | UTHR | 3 | PHASE3 | Treprostinil |
| Insmed Incorporated | INSM | 2 | PHASE3 | Treprostinil Palmitil |
| Bristol-Myers Squibb Company | BMY | 1 | PHASE3 | BMS-986278 |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| aTyr Pharma, Inc. | ATYR | 1 | PHASE2 | efzofitimod |
| Avalyn Pharma Inc | AVLN | 1 | PHASE2 | AP01 |
| Liquidia Corporation | LQDA | 1 | - | LIQ861 |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Efzofitimod is an investigational small molecule being developed for pulmonary sarcoidosis, interstitial lung disease, and severe pneumonia related to SARS-CoV-2 (COVID-19). It is being studied as a treatment for these respiratory conditions.
Efzofitimod is being developed by aTyr Pharma, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ATYR.
Efzofitimod is in Phase 3 clinical development. A Phase 3 trial for pulmonary sarcoidosis has been completed, and a Phase 2 trial for systemic sclerosis-related interstitial lung disease is currently recruiting participants.
Efzofitimod has been studied in several clinical trials. NCT04412668 was a completed Phase 2 trial for COVID-19 severe pneumonia. NCT05415137 was a completed Phase 3 trial for pulmonary sarcoidosis. NCT05892614 is an ongoing Phase 2 trial for systemic sclerosis-related interstitial lung disease.
Yes, Efzofitimod is also known as ATYR1923. The Phase 2 trial for COVID-19 severe pneumonia, NCT04412668, was originally titled to evaluate ATYR1923, which is the same drug as Efzofitimod.